Posthospital Discharge Medical Care Costs and Family Burden Associated with Osteoporotic Fracture Patients in China from 2011 to 2013

Zhao, Xie; Burge, Russel; Yang, Yicheng; Du, Fen; Lu, Tie; Huang, Qiang; Ye, Wenyu; Xu, Wei

doi:10.1155/2015/258089

Cited by 10 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Direct economic burden was regarded as the sum of direct and indirect medical cost. Direct medical cost comprised expenses of outpatient services/visits, pharmaceutical drugs, nursing care, and other factors directly related to diagnosis and treatment; indirect medical cost covered transportation, nutritional services, and others [12]. Indirect economic burden monetarily assessed productivity loss of patients and individuals caring for patients [13]; however, we assumed that patients aged >65 years and their parents, wives/husbands, or friends caring for them did not lose work time due to being retired.…”

Section: Prospective Surveymentioning

confidence: 99%

Disease burden of hepatitis E in a rural population in China: a community-based survey

et al. 2017

View full text Add to dashboard Cite

This study aimed to estimate the disease burden of hepatitis E in a rural region in China. A total of 489 hepatitis E cases were reported according to a community-based survey in an active hepatitis surveillance system between 2008 and 2015, the questionnaire and record-review methods were constructed to evaluate the economic and health burden of hepatitis E virus infections from societal perspectives. All costs were converted to US$ in 2015. The age-standardized cumulative incidence rate was 107·9/100 000, and the median age-standardized annual incidence rate was 16·5/100 000. The median direct, indirect, and intangible cost were $1046·0, $49·1, and $77·3/patient, respectively, and the median economic burden per patient was $1836·5, which accounted for 51·2% of per capita disposable income. Moreover, the median quality-adjusted life year and visual analogue scale score were 0·7 and 70·0/case, respectively. Both economic burden and health burden of inpatients was more serious than that of outpatients (P < 0·001). Disease burden of hepatitis E is heavy on patients, their families, and society. More studies on the disease burden of hepatitis E are necessary to increase social awareness of the disease and confirm reasonable disease-control measures.

show abstract

Section: Prospective Surveymentioning

confidence: 99%

Disease burden of hepatitis E in a rural population in China: a community-based survey

et al. 2017

View full text Add to dashboard Cite

show abstract

“…From 2002 to 2006, the rates of hip fracture over age 50 years have increased 58% in women and 49% in men based on a population-based study in Beijing [ 5 ]. Most important of all, the most serious consequences of osteoporotic fractures, especially hip fracture, are the increasing proportion of mortality and disability [ 6 ]. Therefore, interventions to treat POP or prevent osteoporotic fractures should be implemented.…”

Section: Introductionmentioning

confidence: 99%

Qianggu capsule for the treatment of primary osteoporosis: evidence from a Chinese patent medicine

Wei

Ai-li

Shen

et al. 2017

BMC Complement Altern Med

View full text Add to dashboard Cite

BackgroundQianggu Capsule, a Chinese patent medicine, has been widely applied in the clinical practice of primary osteoporosis (POP) in recent years. This study aims to summarize the effectiveness and safety of Qianggu Capsule in treating POP.MethodsWe searched seven electronic databases, all searches ended in 30 September, 2015. All randomised controlled trials comparing the efficacy of Qianggu Capsule treatment with no treatment, placebo or conventional therapy for POP were included. Combined therapies of Qianggu Capsule were also included. Cochrane risk of bias tool was used to assess methodological quality of primary studies. Revman 5.2.0 software was used for data analysis.ResultsTen trials were enrolled. The combined effect showed that Qianggu Capsule plus Caltrate D was better than Caltrate D on lumbar spine bone mineral density (BMD) (MD = 0.05 g/cm2; 95% CI: 0.02–0.07; P = 0.0004), femoral neck BMD (MD = 0.03 g/cm2; 95% CI: 0.01–0.05; P = 0.001), femoral great trochanter BMD (MD = 0.04 g/cm2; 95% CI: 0.03–0.06; P < 0.001). Meta-analysis exhibited a significant antiosteoporosis effect of Qianggu Capsule on femoral neck BMD (MD = 0.03 g/cm2; 95% CI: 0.01–0.05; P = 0.003) and femoral trochanteric BMD (MD = 0.07 g/cm2; 95% CI: 0.02–0.12; P = 0.006) compared with α-D3 capsule. However, the methodological quality of included studies was low. Constipation and dry mouth were the most common adverse drug reactions of Qianggu Capsule. Finally the evidence level was evaluated to be low or very low.ConclusionsThe effect of Qianggu Capsule for POP was supported in improving BMD. Due to the methodological drawbacks of the included studies, the conclusions should be treated with caution for future research.

show abstract

“…In China, take for example, recently published data indicates that the median of the per-admission inpatient costs for osteoporotic fractures is ¥18,587 [ 7 ]. After post-discharge, the average direct medical cost, indirect medical cost, and caregiver lost income associated with osteoporosis-related fracture still totaled ¥7,886 [ 8 ]. Therefore, treatment of osteoporosis has positive significance to prevent fractures, especially for POP patients.…”

Section: Introductionmentioning

confidence: 99%

Moxibustion treatment for primary osteoporosis: A systematic review of randomized controlled trials

Huang

Kong

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

Primary osteoporosis (POP) has a serious impact on quality of life for middle-aged and elderly, which particularly increase the risk of fracture. We conducted the systematic review to evaluate the effects of moxibustion for POP in randomized controlled trials (RCTs).Eight databases were searched from their inception to July 30, 2016. The RCTs reporting the moxibustion as a monotherapy or in combination with conventional therapy for POP were enrolled. The outcomes might be fracture incidence, quality of life, clinical symptoms, death attributed to osteoporosis, adverse effect, bone mineral density (BMD), and biochemical indicators. Literature selection, data abstraction, quality evaluation, and data analysis were in accordance with Cochrane standards.Thirteen trials including 808 patients were included. Meta-analysis was not conducted because of the obvious clinical or statistical heterogeneity. Limited evidence suggested that moxibustion plus anti-osteoporosis medicine might be more effective in relieving the pain (visual analogue scale scores average changed 2 scores between groups, 4 trials), increasing the BMD of femoral neck (average changed 0.4 g/cm2 between groups, 3 trials), and improving the level of bone gla protein, osteoprotegerin and bone alkaline phosphatase (2 trials) compared with anti-osteoporosis medicine alone. However, the quality of previous studies was evaluated as generally poor. The safety evidence of moxibustion was still insufficient. Due to the paucity of high-quality studies, there was no definite conclusion about the efficacy and safety of moxibustion treating POP although parts of positive results were presented. Future research should pay attention to the dose-response relation and fracture incidence of moxibustion for POP.

show abstract

Posthospital Discharge Medical Care Costs and Family Burden Associated with Osteoporotic Fracture Patients in China from 2011 to 2013

Cited by 10 publications

References 17 publications

Disease burden of hepatitis E in a rural population in China: a community-based survey

Disease burden of hepatitis E in a rural population in China: a community-based survey

Qianggu capsule for the treatment of primary osteoporosis: evidence from a Chinese patent medicine

Moxibustion treatment for primary osteoporosis: A systematic review of randomized controlled trials

Contact Info

Product

Resources

About